evipedia.ai
← Back

Glutamine for Health & Longevity

Evidence Review created on 09/09/2026 using AI4L / Opus 5

Also known as: L-Glutamine, Gln, Levoglutamide, Alanyl-glutamine, Glutamine Peptides

Motivation

Glutamine (L-glutamine) is the most plentiful free amino acid in human blood and muscle. The body makes its own supply, so it is not required from food — yet during illness, injury, heavy training, or major surgery, demand can outrun production, and levels fall. That pattern led researchers to call it “conditionally essential” and made it one of the most widely sold amino acid powders in the world.

Its appeal rests on where it goes. Glutamine is the preferred fuel of the cells lining the gut and of white blood cells, and it feeds the body’s main internal antioxidant. Hospitals have used it for decades in burns, surgery, and cancer care, and a purified version is licensed as a medicine for sickle cell disease. At the same time, a large intensive-care trial found more deaths among the sickest patients who received it, and cancer biologists study drugs designed to block glutamine rather than supply it.

This review examines what glutamine is, what the human evidence shows for gut, metabolic, and recovery outcomes, where the harms lie, and how the practical details of dosing and monitoring are handled.

Benefits - Risks - Protocol - Conclusion

High-level overviews of glutamine from independent experts and from the primary academic literature, selected for depth rather than for the number of times the compound is named.

  • Considerations for glutamine supplementation as it relates to gut health and cancer - Rhonda Patrick

    A video segment in which Dominic D’Agostino separates glutamine’s gut-repair value from its role as a tumor fuel, and argues against supplementation in gastrointestinal and liver cancers.

  • Nutrients For Brain Health & Performance - Andrew Huberman

    A solo episode with a dedicated L-glutamine chapter covering a 1–10 g daily range, gut-brain signaling, sugar craving suppression, and the cancer caution that accompanies amino acid loading.

  • What is Glutamine? - Chancellor Faloon

    A compact consumer overview that walks through three randomized gut trials — microbiota composition, exercise-induced permeability, and irritable bowel syndrome — and lists the immune and exercise findings. Published by a company that sells glutamine.

  • Glutamine Supplementation Has Anti-Aging Potential - Larisa Sheloukhova

    The only longevity-framed treatment found, summarizing cell, fly and mouse work linking glutamine availability to cellular senescence (cells that stop dividing but persist), autophagy (the cell’s self-recycling process) and accelerated-aging phenotypes.

  • Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation - Cruzat et al., 2018

    The standard narrative review of glutamine biochemistry: inter-organ trafficking between gut, liver and muscle, immune-cell consumption rates, and why plasma levels are a poor guide to supplementation need.

No qualifying content was found from two priority experts. peterattiamd.com returns nothing from its own search box for “glutamine”, and its glutamine tag archive holds only two podcast episodes in which the compound is a single chapter inside a broader discussion — a Zone 2 exercise episode (Zone 2 is training at a moderate, sustainable aerobic intensity) and a ketosis-and-cancer question-and-answer session whose glutamine segment sits behind the membership wall. chriskresser.com returned only incidental mentions of glutamine as a bone-broth constituent inside broader gut-healing articles. Neither platform offers a treatment of the compound in substantial depth, so neither was included rather than padding the list with marginal material.

Grokipedia

  • Glutamine

    A dedicated encyclopedic entry covering glutamine’s chemistry, its status as the most abundant free amino acid in plasma, biosynthesis and catabolism, and its clinical and supplemental uses.

Examine

  • Glutamine

    Grades fifteen outcomes across eight trials and four pooled analyses covering 4,530 participants, with its highest grades going to pancreatitis (inflamed pancreas) and mucositis (mouth-lining inflammation) symptoms, and dosing spanning 0.6–60 g daily.

ConsumerLab

  • L-Glutamine Supplements Review

    Independent laboratory testing of eight retail products, with cost ranging from four to fifty-six cents per gram, plus dose-graded safety notes on gastrointestinal effects, kidney injury, anti-epilepsy drugs and mania.

Systematic Reviews

The pooled human evidence on glutamine — drawn from systematic reviews and meta-analyses (which statistically combine the results of many separate trials into a single estimate) — spanning its claimed benefits in athletes, the gut and metabolic health, and its principal safety signal in critical illness.

Mechanism of Action

Glutamine is the most abundant free amino acid in plasma and muscle, and its plasma half-life is short, roughly 30–60 minutes. Skeletal muscle builds it from glutamate and ammonia using glutamine synthetase (the enzyme that traps waste nitrogen into a transportable form), and gut, kidney and immune cells break it down again using glutaminase (the enzyme that releases that nitrogen).

Three roles dominate. First, fuel: glutamine’s carbon skeleton enters the tricarboxylic acid cycle (the mitochondrial energy production loop) as alpha-ketoglutarate, and enterocytes (the cells lining the intestine) and lymphocytes consume it at rates matching or exceeding glucose. Second, nitrogen donation: glutamine supplies nitrogen for nucleotide synthesis and, via glutamate, for glutathione, the body’s principal internal antioxidant. Third, barrier maintenance: glutamine availability supports tight-junction proteins (the seals between neighboring gut cells) and stress-protection proteins in the intestinal lining.

Glutamine also drives nutrient sensing. Its influx powers leucine uptake through the SLC7A5 transporter (the carrier that swaps glutamine out of a cell in exchange for leucine), activating mTOR (mechanistic target of rapamycin, the growth-signaling hub that switches cells from repair to building).

Two mechanistic readings compete. The pro-supplementation reading holds that catabolic stress drains the pool faster than muscle can refill it. The counter-reading notes that most oral glutamine is extracted first-pass by gut and liver, that plasma levels barely move, and that many tumors are glutamine-dependent — the premise behind glutamine-antagonist cancer drugs.

Historical Context & Evolution

Glutamine was isolated from beet juice in 1883 and classified for most of the twentieth century as nonessential, since the body synthesizes it. Cell-culture work in the 1950s complicated that label: cultured human cells required glutamine at concentrations far above any other amino acid.

The modern story begins in the 1970s and 1980s with surgical metabolism research, notably by Douglas Wilmore’s group at Harvard, which documented steep falls in muscle and plasma glutamine after trauma, sepsis and burns and proposed the term “conditionally essential”. European clinical nutrition adopted intravenous alanyl-glutamine dipeptides through the 1990s, and sports nutrition adopted the powder after a small 1995 study reported that a 2 g oral dose raised plasma bicarbonate and circulating growth hormone.

Two reversals followed. In 2013 the REDOXS trial reported higher mortality among critically ill patients with multiorgan failure given high-dose glutamine, and the 2014 MetaPlus trial found higher six-month mortality in a medical subgroup; intensive-care use contracted sharply. In the other direction, a phase 3 trial led to United States approval of pharmaceutical-grade L-glutamine for sickle cell disease in 2017. European regulators reached the opposite conclusion on the same dossier, and the application was withdrawn in 2019 after a negative opinion. Both positions rest on the same trial; neither has been superseded.

Expected Benefits

High 🟩 🟩 🟩

Reduced Severity of Cancer-Treatment Mucositis

Oral glutamine lowers the severity of mouth and throat ulceration caused by radiotherapy and chemotherapy, plausibly by supplying the fuel that rapidly dividing mucosal cells need to regenerate. The evidence base is a meta-analysis of 11 randomized controlled trials (studies in which participants are assigned to treatment or control by chance) covering 922 head-and-neck cancer patients, supported by an independent systematic review. Overall incidence of any-grade ulceration was unchanged; only severity shifted.

Magnitude: Severe ulceration was cut to a relative risk of 0.41 (the pooled rate in the glutamine group as a fraction of the control rate), and mean maximal grade, opioid analgesic use, tube feeding and treatment interruption all fell, while any-grade incidence was essentially unchanged at a relative risk of 0.94.

Improved Glycemic Control

Glutamine lowers fasting blood glucose and blunts the post-meal glucose rise, acting partly through release of glucagon-like peptide-1 (a gut hormone that amplifies insulin secretion in proportion to glucose). Evidence spans a meta-analysis of 12 randomized trials for fasting glucose and two crossover trials showing augmented glucagon-like peptide-1 and insulin release and reduced early post-meal glycemia. Effects are modest and heterogeneity between trials (the degree to which their results disagreed) was high.

Magnitude: Fasting plasma glucose fell with a standardized mean difference of −0.73 (a pooled effect size expressed in units of the spread of the data; 95% confidence interval — the range within which the true value most likely sits — −1.35 to −0.11) across 12 trials; a 30 g oral dose reduced the 0–60 minute post-meal glucose response in type 2 diabetes.

Lower Systemic Inflammation

Glutamine reduces C-reactive protein, a liver-produced marker that also tracks cardiovascular and mortality risk. The proposed route is combined support of glutathione synthesis and of gut barrier integrity, which lowers the passage of bacterial fragments into circulation. The same 12-trial meta-analysis found the effect with no measurable heterogeneity between studies, unusual in this literature. Trials were short and mostly conducted in metabolically unwell populations.

Magnitude: C-reactive protein fell with a standardized mean difference of −0.58, statistically significant and with zero measured heterogeneity across the pooled trials.

Medium 🟩 🟩

Fewer Sickle Cell Pain Crises

Pharmaceutical-grade L-glutamine reduces the frequency of vaso-occlusive pain episodes (attacks in which misshapen red cells block small blood vessels) in sickle cell disease, apparently by improving the red cell’s capacity to handle oxidative stress. The basis is a single phase 3 randomized trial in 230 patients over 48 weeks, funded by Emmaus Medical, which markets the resulting product — a direct financial interest in the outcome. European regulators judged the same dataset insufficient and the marketing application was withdrawn. Dropout exceeded a third.

Magnitude: Median pain crises over 48 weeks were 3.0 with glutamine versus 4.0 with placebo, and median hospitalizations 2.0 versus 3.0.

Relief of Post-Infectious Irritable Bowel Syndrome and Intestinal Barrier Repair ⚠️ Conflicted

Glutamine repairs a leaky intestinal lining and, where symptoms stem from that leak, resolves them. A randomized trial in 106 adults with diarrhea-predominant irritable bowel syndrome after an enteric infection produced a fourteen-fold difference in response rate and normalized permeability. Against this, a meta-analysis of 10 permeability trials found no overall effect, with benefit confined to doses above 30 g daily. Net reading: the effect appears real but requires both a damaged barrier and a high dose.

Magnitude: 79.6% of the glutamine group versus 5.8% of placebo achieved a ≥50-point fall on the Irritable Bowel Syndrome Severity Scoring System over eight weeks at 5 g three times daily.

Greater Knee Muscle Strength and Power in Older Adults

Thirty days of oral glutamine raised machine-measured knee extension and flexion strength in women aged 60–80, alongside improved glycemic and antioxidant markers; strength gains were larger in the sedentary participants, while average power rose only in those who also exercised. The evidence is a single randomized trial in 44 women. This is the one human dataset addressing glutamine specifically in an ageing musculoskeletal context, and it has not been replicated.

Magnitude: Knee extensor peak torque rose 20.6% and flexor 47.6% in the non-exercising glutamine subgroup, and 16.1% and 21.4% in the exercising subgroup, with Cohen effect sizes of 0.78 to 1.31; average power of the extensor rose 12.7% only where supplementation was combined with regular physical exercise.

Low 🟩

Faster Strength Recovery and Reduced Soreness After Eccentric Exercise ⚠️ Conflicted

A crossover trial in 16 adults found faster strength recovery and lower soreness over 72 hours after eccentric knee-extension work (repetitions performed while the muscle lengthens under load). The 25-trial athlete meta-analysis found no performance benefit. Net reading: recovery benefit is plausible; performance benefit is not.

Magnitude: Relative peak torque at 180°/second was 91±8% of baseline at 72 hours versus 86±7% on placebo; soreness at 48 hours was 2.6±1.4 versus 3.9±1.2.

Fewer Infections After Prolonged Strenuous Exercise ⚠️ Conflicted

Glutamine taken around endurance exercise may lower self-reported infection in the following week, plausibly by fuelling immune cells depleted after such efforts. The basis is a 151-athlete controlled study; the 25-trial pooled analysis found no immune-cell change. Net reading: the symptom signal stands, the cellular one does not.

Magnitude: 19% of the glutamine group reported an infection in the seven days after exercise versus 51% on placebo, across 151 completed questionnaires.

Small Reduction in Body Weight ⚠️ Conflicted

Pooled athlete trials show a small drop in body mass, with lean mass and body fat percentage unchanged. The source is the same 25-trial meta-analysis whose own conclusion reports no body-composition effect. Net reading: weight falls slightly, but what was lost is unknown.

Magnitude: Weighted mean difference −1.36 kg (95% confidence interval −2.55 to −0.16) across the pooled trials, with no accompanying change in lean body mass or body fat percentage.

Speculative 🟨

Acute Increase in Circulating Growth Hormone

A 1995 study in nine healthy adults found a 2 g oral dose raised plasma growth hormone at 90 minutes. It used prior-week time controls, not placebo, was never replicated, and no outcome was linked.

Favorable Shift in Gut Microbiota Composition

Two weeks of 30 g daily shifted the Firmicutes-to-Bacteroidetes ratio downward in 33 overweight adults versus alanine control. That ratio is an unvalidated biomarker with no established link to clinical outcomes. It was a pilot.

Reduced Sugar and Alcohol Cravings

Rests on gut amino acid sensing and on expert anecdote rather than controlled data. No randomized trial has measured craving or intake as an endpoint; the underlying reports date to mid-twentieth-century alcoholism case series.

Slower Cellular Senescence

Glutamine supplementation reduced oxidative-stress-induced senescence and rescued an accelerated-aging phenotype in mice, while deprivation shortened fly lifespan, via mTOR and autophagy signaling. Basis is cell, insect and rodent work only; no human ageing endpoint exists.

Benefit-Modifying Factors

  • Amino acid transporter variants: SLC1A5 and SLC38A family polymorphisms (genetic variants of the proteins that carry glutamine into cells) alter uptake efficiency, plausibly shifting the dose needed for gut and immune effects. No trial has yet stratified outcomes by these variants.

  • Sickle genotype: The only licensed benefit is confined to the two sickle cell genotypes studied — hemoglobin SS and S-beta-zero-thalassemia (an inherited hemoglobin defect). Outside those, the pain-crisis finding carries no read-across, and the trial excluded other hemoglobin disorders.

  • Baseline glutamine and inflammation: Benefit concentrates where the pool is depleted. Low plasma glutamine, raised C-reactive protein, or a raised lactulose-to-mannitol permeability ratio mark the states in which trials found effects; replete, healthy baselines predict little movement.

  • Sex: In the eccentric-exercise recovery trial men produced greater normalized peak torque gains than women, while the older-adult strength trial enrolled women only. No mechanism is established and no trial was powered for a sex interaction.

  • Pre-existing conditions: Post-infectious irritable bowel syndrome, active cancer treatment, and burns are the settings with measurable benefit. Cirrhosis (advanced liver scarring) and reduced kidney function invert the balance, because impaired ammonia clearance turns the nitrogen load into a liability.

  • Age: The one trial in adults over 60 found strength and glycemic gains in sedentary and exercising participants alike, with added power only where exercise was present. Age also raises exposure to the two documented harms, since kidney reserve and ammonia handling both decline.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Increased Mortality in Critical Illness with Multiorgan Failure ⚠️ Conflicted

High-dose glutamine given early to intensive-care patients with failure of two or more organ systems increased death rates: REDOXS randomized 1,223 ventilated adults to intravenous plus enteral glutamine, and mortality rose significantly. The MetaPlus trial, combining glutamine with omega-3 fatty acids, selenium and antioxidants, found higher six-month mortality in its medical subgroup. Against this, pooled analyses report no mortality effect overall, one conclusively. Proposed mechanism: nitrogen and ammonia loading beyond kidney and liver clearance. Net reading: harm holds at hospital dose by dual route in multiorgan failure, not elsewhere.

Magnitude: 28-day mortality 32.4% versus 27.2%, adjusted odds ratio 1.28 (the multiple by which the odds of dying rose) with a 95% confidence interval of 1.00 to 1.64; MetaPlus six-month mortality 54% versus 35% in the medical subgroup, hazard ratio 1.57 (the equivalent multiple applied to risk over time), 95% confidence interval 1.03 to 2.39.

Dose-Dependent Gastrointestinal Symptoms

Discomfort, nausea, belching and upper abdominal pain rise with dose, attributed partly to undissolved glutamine crystals in the beverage. A crossover tolerance study in 14 healthy men found accumulated symptoms over 24 hours were greater at the highest dose than at the lower two, though most remained mild. The sickle cell phase 3 trial independently reported more low-grade nausea, non-cardiac chest pain, fatigue and musculoskeletal pain. Independent laboratory testing places the practical threshold near 10 g daily.

Magnitude: Direction is a dose-graded increase, holding above roughly 0.6 g per kg fat-free mass in a single sitting and above about 10 g daily in ordinary use, with dry mouth, headache and dizziness reported at 30 g and above. The tolerance study reports symptom scores rather than an incidence figure.

Medium 🟥 🟥

Elevated Blood Ammonia

Glutamine is broken down in the gut and kidney, releasing ammonia that a healthy liver converts to urea. Where that conversion is impaired the load accumulates. An oral glutamine challenge is used clinically as a provocation test precisely because it raises blood ammonia and unmasks minimal hepatic encephalopathy (the confusion and slowed cognition of liver failure), and the abnormal response predicts later overt episodes. Healthy livers absorb the load without measurable effect.

Magnitude: In cirrhosis a 10 g oral load raises venous ammonia, and a rise above 32 µg/dL at 60 minutes marks an impaired response; combined with a raised fasting ammonia it identified a group carrying 4.67 times the risk of a first encephalopathy episode (95% confidence interval 2.19 to 9.98) against a background incidence of 28.3% over six years, and an impaired response alongside minimal encephalopathy carried 5.5 times the mortality risk (95% confidence interval 1.81 to 16.6).

Low 🟥

Acute Kidney Injury

A published clinical observation describes tubular damage and acute kidney injury in a patient taking 18 g of L-glutamine daily, with increased single-nephron ammonia production proposed as the mechanism. Independent laboratory testing flagged the same report in a 2025 safety update. One case, no controlled data.

Magnitude: Not quantified in available studies. Only a single case report exists, so no incidence, relative risk or dose-response figure can be derived.

Neuropsychiatric Activation

A 1984 case report links L-glutamine to a manic episode, and independent laboratory testing records member reports of dizziness, nausea and anxiety, plus a standing caution for bipolar disorder. Glutamine is a glutamate precursor, giving biological plausibility. No controlled trial has measured psychiatric endpoints.

Magnitude: Not quantified in available studies. The evidence is one case report and post-marketing consumer reports, so no controlled trial has measured psychiatric outcomes at any dose.

Speculative 🟨

Support of Tumor Growth

Many tumors are glutamine-dependent, and glutamine-antagonist drugs are in trials on that premise. Whether supplemental glutamine accelerates existing disease is untested in people; the basis is cell-culture and animal work only.

Reduced Anticonvulsant Efficacy

Independent laboratory testing flags a concern that glutamine may interfere with anti-epilepsy drugs, since it is the precursor of the excitatory neurotransmitter glutamate. The basis is mechanistic inference alone; no seizure-outcome study exists.

Risk-Modifying Factors

  • Urea cycle variants: Ornithine transcarbamylase deficiency carriers (including asymptomatic female carriers of this X-linked ammonia-clearing enzyme defect) cannot buffer a nitrogen load, converting a routine dose into a hyperammonemia (toxic ammonia build-up) risk.

  • Baseline kidney, liver and ammonia markers: A reduced estimated glomerular filtration rate (a calculated measure of kidney filtering capacity), raised alanine aminotransferase (a liver-damage enzyme), or raised fasting ammonia each mark the clearance limits behind the kidney and encephalopathy signals.

  • Sex: No sex difference in adverse events has been demonstrated in trials. The one asymmetry is genetic: female ornithine transcarbamylase carriers can decompensate under nitrogen loading despite normal routine bloodwork.

  • Pre-existing conditions: Cirrhosis, chronic kidney disease, multiorgan failure and active gastrointestinal or hepatic malignancy each convert glutamine from a neutral nutrient into a plausible hazard, on ammonia-clearance or tumor-fuel grounds.

  • Age: Kidney reserve and hepatic urea-cycle capacity both fall with age. The single reported kidney injury occurred in an older patient, and the published caution is directed specifically at older users with reduced kidney function.

Key Interactions & Contraindications

  • Lactulose and rifaximin (hepatic encephalopathy therapy): Caution — glutamine raises gut ammonia production, directly opposing the effect these agents are prescribed to achieve. Consequence: loss of encephalopathy control. Mitigation: avoid glutamine entirely while on either agent.

  • Anticonvulsants (anti-seizure drugs: lamotrigine, valproate, levetiracetam, carbamazepine): Caution — glutamine is the precursor of glutamate, the brain’s main excitatory transmitter, and may theoretically lower seizure threshold. Consequence: reduced seizure control. Mitigation: avoid in treated epilepsy.

  • Glutamine-antagonist chemotherapy (DON, sirpiglenastat/DRP-104): Absolute contraindication — supplemental glutamine directly opposes the drug’s mechanism. Consequence: loss of anti-tumor effect. Mitigation: no co-administration; separation in time does not resolve the conflict.

  • Somatropin (recombinant growth hormone): Intended combination in short bowel syndrome, where glutamine is licensed alongside it. Consequence: additive intestinal adaptation. Mitigation: none needed; the pairing is the approved regimen.

  • Glucose-lowering drugs (metformin, sulfonylureas, insulin, semaglutide): Caution — glutamine lowers fasting and post-meal glucose and raises glucagon-like peptide-1. Consequence: additive hypoglycemia. Mitigation: increase glucose monitoring for the first four weeks.

  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin): Additive and favorable — glutamine has been studied for protection of the stomach lining against these agents. Consequence: reduced gastric injury. Mitigation: none required.

  • Competing amino acid supplements (branched-chain amino acids, arginine, glycine, N-acetylcysteine): Caution — these share transporters with glutamine, reducing absorption. N-acetylcysteine and glycine are additive for glutathione synthesis. Mitigation: separate glutamine from other amino acids by two hours.

  • Probiotics and zinc carnosine: Additive — both are used alongside glutamine in gut-barrier protocols and act on the same tight-junction endpoint. Consequence: greater barrier repair. Mitigation: none; a trial of glutamine plus Limosilactobacillus reuteri is underway.

  • Other interventions: Protein-restricted and ketogenic protocols alter glutamine handling; endurance and heat exposure raise gut permeability and thereby the plausible benefit window. Neither constitutes a contraindication.

Populations who should avoid Glutamine:

  • Cirrhosis of Child-Pugh Class B or C (a severity score for liver failure), or any history of hepatic encephalopathy
  • Chronic kidney disease with estimated glomerular filtration rate below 30 mL/min/1.73 m²
  • Intensive-care patients with failure of two or more organ systems, within the first 24 hours of admission
  • Active gastrointestinal or hepatic malignancy, and anyone receiving glutamine-antagonist chemotherapy
  • Diagnosed urea cycle disorders, including asymptomatic ornithine transcarbamylase deficiency carriers
  • Treated epilepsy, and bipolar disorder with a history of mania
  • Documented monosodium glutamate hypersensitivity, in whom reactions are reported at ordinary doses

Risk Mitigation Strategies

  • Baseline kidney and liver screening: A basic metabolic panel and liver panel establish estimated glomerular filtration rate and alanine aminotransferase, the two markers that separate safe users from those exposed to the kidney-injury and ammonia signals.

  • Low starting dose with slow titration: Protocols begin at 5 g daily for one week, rising to 10 g and then 15 g at weekly intervals. This mitigates the dose-graded nausea, belching and abdominal discomfort seen in tolerance testing.

  • Single-dose cap of 10 grams: Splitting a daily total into doses of 10 g or less mitigates the acute upper gastrointestinal symptoms that rise sharply above roughly 0.6 g per kg fat-free mass in one sitting.

  • Full dissolution in at least 250 mL of water: Undissolved crystals were identified as a probable driver of early post-dose symptoms; complete dissolution before drinking mitigates nausea and upper abdominal pain.

  • Doses above 30 grams confined to short courses: The permeability benefit appears only above 30 g daily, but so do dry mouth, headache and dizziness. Limiting such doses to under two weeks mitigates cumulative exposure.

  • Suspension during acute illness or hospitalization: Stopping glutamine on admission, and during any acute febrile or septic illness, mitigates the mortality signal seen when it was given early to patients with multiorgan failure.

  • Repeat kidney-function testing at 8–12 weeks: An estimated glomerular filtration rate and blood urea nitrogen check at 8–12 weeks, then every 6–12 months, mitigates the acute kidney injury reported after sustained daily use near 18 g.

  • Oncology clearance where there is a cancer history: Confirming with the treating oncologist mitigates the theoretical tumor-fuelling risk and the direct antagonism with glutamine-blocking chemotherapy agents.

Therapeutic Protocol

  • Standard clinical gut protocol: 5 g of free L-glutamine powder three times daily for eight weeks, the regimen that produced the post-infectious irritable bowel syndrome result. Taken between meals on an empty stomach.

  • Conventional clinical nutrition approach: Short, supervised high-dose courses, often as the alanyl-glutamine dipeptide for stability, targeting mucosal repair around surgery or radiotherapy. Developed within the European Society for Clinical Nutrition and Metabolism tradition, whose guideline work draws feed-industry funding.

  • Integrative and functional-medicine approach: 5–15 g daily of free-form powder as one element of a layered gut-repair regimen with zinc carnosine and probiotics, run for 4–12 weeks. Popularised by functional-medicine practitioners such as Chris Kresser rather than by trial evidence.

  • Sports and general-wellness approach: 1–10 g daily, taken after training or before bed, promoted by Andrew Huberman among others for gut and immune support and craving control. Neither approach is the established default; the evidence bases differ rather than compete.

  • Best time of day: Empty stomach, either on waking or between meals, to minimise competition from dietary amino acids. Exercise protocols place the dose immediately post-training; craving protocols spread small doses across the day.

  • Half-life: Plasma half-life is short, roughly 30–60 minutes, with 50–70% of an oral dose extracted first-pass by gut and liver. Circulating levels return to baseline within about 90 minutes of a modest dose.

  • Single versus split dosing: Split dosing dominates. It follows from the short half-life, sustains gut lumen exposure across the day, and reduces the acute gastrointestinal symptoms that track single-dose size rather than daily total.

  • Genetic considerations: SLC1A5 and SLC38A transporter variants plausibly shift the effective dose. Ornithine transcarbamylase and other urea cycle variants argue for avoidance rather than adjustment, since the limiting factor is ammonia clearance, not uptake.

  • Sex-based differences: The only signal is greater strength-recovery response in men in a small crossover trial. No dosing difference is established, and the older-adult strength trial used a single dose in women only.

  • Age-related considerations: Protocols for adults over 60 start at 5 g and confirm kidney function first, since both documented harms scale with reduced clearance. The one trial in this group used 10 g daily for 30 days without adverse effects.

  • Baseline biomarkers: Plasma glutamine, C-reactive protein, fasting glucose and a permeability ratio define the starting point. Benefit in trials concentrated in depleted or inflamed baselines, so these values set expectations rather than gate treatment.

  • Pre-existing conditions: Post-infectious irritable bowel syndrome supports the higher 15 g daily regimen. Liver or kidney impairment, active malignancy and treated epilepsy move the protocol to avoidance rather than dose reduction.

Discontinuation & Cycling

  • Short-term by default: Gut-repair protocols run 4–12 weeks, matching the trial durations. Only the licensed sickle cell indication is framed as indefinite; no longevity rationale for lifelong use has been tested in humans.

  • No documented withdrawal effects: Endogenous synthesis resumes without interruption, since supplementation never suppresses glutamine synthetase. Trials that stopped supplementation at 8 weeks or 30 days reported no rebound symptoms or discontinuation events.

  • Tapering not required: No trial has used or needed a taper. Abrupt cessation is the pattern in every published protocol, including the 48-week sickle cell trial and the 30-day older-adult strength study.

  • Cycling is convention, not evidence: Common practice runs 8 weeks on, 4 weeks off, reasoned from the growth-signaling pathway glutamine activates and from limiting cumulative nitrogen load. No trial has compared continuous with cycled administration.

Sourcing and Quality

  • Free-form L-glutamine is the default: Almost all retail product is free-form L-glutamine produced by bacterial fermentation, so “free form” label claims carry no premium. The D-isomer has no role and should not appear.

  • Glutamine peptides are a labelling trap: Products labeled “glutamine peptides” are typically hydrolysed wheat protein delivering far less actual glutamine per gram than the label implies, and they are unsuitable where gluten is a concern.

  • Third-party testing: NSF Certified for Sport and Informed Sport verify against banned substances and label accuracy; United States Pharmacopeia verification and ConsumerLab approval confirm identity and content. Amino acid powders are a common adulteration target.

  • Price spread is large for an identical molecule: Independent testing found retail cost ranging from four to fifty-six cents per gram across approved products, a fourteen-fold spread with no corresponding difference in the compound delivered.

  • Brands subjected to independent testing: ConsumerLab’s most recent review tested products from BulkSupplements.com, GNC, NOW, Nutricost, Pure Encapsulations, Swanson and Thorne. Pharmaceutical-grade material is available only as the prescription sickle cell product.

  • Storage and stability: Glutamine degrades in aqueous solution and with heat, converting to pyroglutamate and ammonia. Powder is mixed immediately before drinking and never added to hot liquids or pre-mixed the night before.

Practical Considerations

  • Time to effect: Glycaemic and hormone responses are acute, within 90 minutes. Mucositis protection registers across a radiotherapy course. Gut symptom relief took the full eight weeks in the irritable bowel trial, with strength changes at 30 days.

  • Common pitfall — dosing far below trial levels: Pre-workout blends often supply 1–2 g. Every positive gut trial used 15–30 g daily. Sub-gram amounts inside proprietary blends cannot reproduce those results.

  • Common pitfall — taking it with protein: Whey and food protein already deliver several grams of glutamine and compete for the same transporters. Taking the powder alongside a shake blunts the plasma excursion the protocols depend on.

  • Common pitfall — assuming a muscle-building effect: The pooled athlete evidence found no benefit to muscle mass or performance. Marketing inherited from the 1990s growth hormone finding, which was never replicated or linked to any outcome.

  • Regulatory status: In the United States glutamine is a dietary supplement under DSHEA (the 1994 law governing supplement marketing). Two prescription forms exist: one for sickle cell disease, one with growth hormone for short bowel syndrome. Gut and longevity use is off-label.

  • Cost and payer incentives: Bulk powder costs roughly 20–60 cents daily at 10 g; the prescription form of the same molecule costs far more. Payers favor the supplement, manufacturers the opposite — a structural bias over which form gets funded trials.

Interaction with Foundational Habits

  • Sleep: Direct interaction is absent — glutamine has no sedative or stimulant action and no trial has measured sleep endpoints. The indirect route runs through glutamate synthesis, which underlies the reported anxiety and restlessness in sensitive users. Practical consequence: users prone to evening activation take the final dose before mid-afternoon rather than at bedtime.

  • Nutrition: Direct and substitutive. A mixed diet supplies roughly 3–6 g daily, concentrated in whey, casein, beef, eggs, cabbage and spinach, so supplementation adds to an existing intake. Practical consequence: doses are taken between meals, never in hot liquid, and the daily total counts dietary sources when protein intake is high.

  • Exercise: Potentiating for recovery and gut barrier, neutral for adaptation. Pooled athlete data show no blunting of hypertrophy (muscle growth) or aerobic gains and no enhancement either. Practical consequence: benefit is plausible for endurance work in heat, where a dose-dependent reduction in exercise-induced permeability has been shown; strength athletes gain recovery only.

  • Stress management: Indirect and bidirectional. Cortisol drives glutamine release from skeletal muscle, so chronic psychological or training stress depletes the pool — the same depletion that defines the responsive states in trials. Practical consequence: stress reduction lowers the drain, and the supplement addresses the consequence rather than the cause.

Monitoring Protocol & Defining Success

Baseline testing establishes whether glutamine is likely to help and whether it is safe to take. Before starting, a basic metabolic panel gives kidney function and blood urea nitrogen (the nitrogen waste product measured in blood); a liver panel gives alanine aminotransferase; and fasting glucose, glycated hemoglobin and high-sensitivity C-reactive protein capture the metabolic and inflammatory targets the trials moved. Plasma glutamine and a gut-permeability test are optional additions for those tracking a gut-repair protocol.

Ongoing monitoring is light because the compound is a dietary amino acid. A reasonable cadence is a repeat panel at 8–12 weeks, again at 6 months, then annually while use continues. Protocols apply the earlier 8-week check to people over 60, to those with an estimated glomerular filtration rate below 90, and to daily intakes above 20 grams, since the documented kidney and ammonia signals are dose- and age-related.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Plasma glutamine 500–750 µmol/L Identifies the depleted state in which trials found benefit Conventional range is wider at 420–700 µmol/L; fasting draw, poorly standardized between laboratories
High-sensitivity C-reactive protein Below 0.5 mg/L Tracks the inflammation endpoint that pooled trials moved Conventional cut-off is below 3.0 mg/L; defer testing 2 weeks after any infection or hard training block
Fasting glucose 70–85 mg/dL Tracks the fasting glycemic endpoint of the pooled trials Conventional range extends to 99 mg/dL; requires 10–12 hours fasting, best paired with fasting insulin
Glycated hemoglobin Below 5.3% Confirms the fasting glucose change reflects a sustained shift Abbreviated HbA1c. Conventional threshold is below 5.7%; no fasting needed; unreliable in anemia or recent blood loss
Estimated glomerular filtration rate Above 90 mL/min/1.73 m² Screens for the reduced clearance behind the kidney-injury report Abbreviated eGFR. Conventional adequacy is above 60; creatinine-based estimates read low after heavy resistance training
Blood urea nitrogen 10–16 mg/dL Detects rising nitrogen load before creatinine moves Abbreviated BUN. Conventional range is 7–20 mg/dL; rises with dehydration and high protein intake independently of glutamine
Alanine aminotransferase Below 20 U/L in men, below 18 U/L in women Screens liver capacity to clear the ammonia load Abbreviated ALT. Conventional upper limits near 40 U/L are set from unscreened populations; pair with gamma-glutamyl transferase (a second liver enzyme, raised when bile flow or alcohol is the cause)
Fasting plasma ammonia Below 30 µmol/L Direct check on the mechanism behind the encephalopathy signal Conventional range is 15–45 µmol/L; sample must go on ice to the laboratory within 15 minutes or it reads falsely high
Lactulose-to-mannitol ratio No established target exists; the usable measure is change from the individual’s own pre-supplementation value Quantifies the intestinal barrier defect that predicts response Six-hour urine collection after a sugar drink; assay methods differ enough that only within-laboratory comparison is meaningful

Qualitative markers complement the laboratory picture and often move first:

  • Stool form and frequency, tracked on the Bristol Stool Scale (a seven-point chart of stool consistency)
  • Post-meal bloating, urgency and abdominal discomfort
  • Frequency and duration of upper respiratory infections across a training block
  • Time to recover normal strength and comfort after heavy eccentric work
  • Intensity and timing of sugar cravings, particularly late afternoon
  • Energy stability in the two hours after a carbohydrate-containing meal

Emerging Research

  • Glutamine for irritable bowel syndrome with impaired permeability: NCT06291038, a 60-participant trial at Rouen University Hospital, recruiting since October 2024, testing whether the permeability-selective benefit seen post-infection generalizes to the wider syndrome.

  • Glutamine for insulin resistance in obesity: NCT04883515, 110 participants at Rouen University Hospital, examining oral glutamine’s effect on insulin resistance and functional intestinal disorders — the first adequately sized test of the metabolic signal.

  • Alanyl-glutamine for Clostridioides difficile infection: NCT04305769, a phase 2 trial of 260 participants at the University of Virginia, testing the dipeptide form against recurrence of this hospital-acquired gut infection — the largest ongoing outpatient glutamine trial.

  • Thalidomide plus glutamine for radiation enteritis: NCT06617182, a phase 2 trial enrolling 150 participants, extending the established mucositis benefit from the mouth to the intestine as a combination therapy.

  • Glutamine antagonism as cancer therapy: NCT06027086, a phase 1/2 trial of DRP-104 with durvalumab in 27 patients with fibrolamellar carcinoma (a rare liver cancer). Evidence that starving tumors of glutamine works would weaken the case for supplementing it.

  • Glutamine, mTOR signaling and cellular senescence: Zhou et al., 2022 established the deprivation-senescence link in cells, flies and mice. Whether supplementation alters human ageing markers is the open question this line must answer.

  • Whether further critical-care trials are warranted: Liang et al., 2024 applied trial sequential analysis (a method that tests whether enough patients have been studied to settle a question) and concluded the null mortality result is already firm, arguing that the intensive-care question is settled rather than underpowered.

Conclusion

Glutamine is an amino acid the body already makes in large amounts, and that fact frames everything. Supplementing adds to a pool that is normally full, so the clearest gains appear where the pool has been drained — the damaged gut lining after an infection, the mouth and throat during cancer treatment, and, in a licensed prescription form, the red blood cells of people with an inherited blood disorder. The trials also point to modest improvements in fasting blood sugar and in a common marker of body-wide inflammation. Claims about muscle size and athletic performance are not supported by the combined trial results, though a single small study in older adults found gains in leg strength.

The safety picture is unusual for a nutrient. Everyday doses are well tolerated, with stomach upset the main complaint and clearly more symptoms at higher intakes. But the largest study in seriously ill hospital patients found more deaths in the group given it, and a single published case links long-term heavy use to kidney injury. Laboratory work showing that many tumors grow on glutamine has no counterpart in people.

Much of the supporting material comes from parties with something to sell: the prescription trial was paid for by the company that markets the product, and the most accessible consumer write-ups come from retailers. The nutrition societies shaping hospital feeding guidance draw funding from the firms that make those feeds. The evidence is real but narrow, and the interested parties sit on both sides.

Top - Benefits - Risks - Protocol